People with schizophrenia spectrum disorders often carry a heavy load of metabolic problems, and antipsychotic medications can add to that burden. Those problems, including weight gain and elevated blood sugar, are linked to higher cardiovascular risk and earlier death. This paper asked a narrow question: what do randomized trials say about GLP-1 receptor agonists in exactly this group of patients?
This was a systematic review and meta-analysis of studies in adults. It was not a new experiment, and it was not conducted in animals or cells. The authors gathered existing randomized controlled trials, combined their results statistically, and judged how trustworthy the combined picture is.
What the researchers did
The team followed PRISMA 2020 reporting guidelines and registered their plan in advance on PROSPERO. They searched electronic databases from inception to their final search date and included randomized controlled trials of semaglutide and other GLP-1 receptor agonists in adults with schizophrenia spectrum disorders receiving antipsychotic treatment. They assessed each trial for risk of bias using the Cochrane Risk of Bias 2 tool and rated the overall certainty of evidence with the GRADE approach. Results were pooled using random-effects meta-analyses.
Seven trials met the criteria, together enrolling 446 participants. That is a small evidence base for a question this important.
What they reported
Compared with control, GLP-1 receptor agonist therapy was associated with a statistically significant reduction in body weight, reported as -6.10 with a 95 percent confidence interval from -12.10 to -0.10 and a P value of 0.05. The authors also reported significant reductions in body mass index, waist circumference, and fasting plasma glucose.
Not everything moved. Effects on lipid measures, insulin-related outcomes, and blood pressure were inconsistent and generally did not reach statistical significance. Serious adverse events were less frequent in the intervention group than in the control group, as the abstract describes it.
The heterogeneity problem
The single most important caveat is the statistical heterogeneity. For the weight finding, the authors reported I squared of 99 percent, which means the individual trials disagreed with each other almost completely. When results scatter that widely, a single pooled number is hard to interpret and should be read with caution. The confidence interval for weight also nearly touched zero, and the P value sat right at the 0.05 threshold.
The authors graded certainty of evidence as low to moderate, driven mainly by that heterogeneity and by imprecision. They also noted the small and shorter-duration study population. Their own conclusion is measured: these findings suggest associations, not proof, and stronger trials are needed.
What this does and does not mean
This review points to a signal worth studying further in a group that faces real metabolic risk. It does not establish that GLP-1 receptor agonists reliably improve health outcomes in people with schizophrenia. It reports short-term changes in body measurements and one glucose marker across a handful of small trials, with low to moderate confidence. It says nothing about long-term cardiovascular events or survival.
The authors are explicit that larger, well-designed randomized trials with longer follow-up and standardized outcome reporting are needed before firm claims can be made. That is the honest bottom line.
If you want background on the compound most studied here, see semaglutide. Related GLP-1 compounds discussed in the broader literature include tirzepatide and the investigational retatrutide, which is not legally compoundable.